Evaluation of Intralesional Bleomycin and Triamcinolone Acetonide in the Treatment of Keloids: A Prospective, Randomized, Open‐Label, Comparative Study
International Journal of Dermatology · 2026
DOI: 10.1111/ijd.70554 ↗At a glance
Randomisierte kontrollierte Studie in International Journal of Dermatology, 2026. Written by Divya Ravali Bandaru and 3 co-authors. Institution: Department of Dermatology, Alluri Sitarama Raju Academy of Medical Sciences, Eluru, Andhra Pradesh, India. Major MEDLINE topics: Bleomycin, Triamcinolone Acetonide, Keloid, Glucocorticoids. Cited 1 times so far (Crossref); 22 references. Funded by: Indian Association of Dermatologists, Venereologists and Leprologists (IADVL).
Abstract (original language)
Background
Keloids are benign fibroproliferative scars resulting from dysregulated wound healing and excessive collagen deposition. Despite the availability of multiple therapeutic options, an optimal treatment strategy remains uncertain.
Methods
This prospective, randomized, open‐label comparative study enrolled 136 patients with clinically diagnosed keloids, who were assigned to receive either intralesional bleomycin (Group A, n = 68) or intralesional triamcinolone acetonide (Group B, n = 68). Treatments were administered at 4‐week intervals for four sessions, with follow‐up conducted 2 months after the final session. Outcomes were assessed using the Vancouver Scar Scale (VSS), and responder rates were defined as ≥ 50%, ≥ 75%, and ≥ 90% reductions in VSS. Secondary outcomes included changes in scar height, surface area, and treatment‐related adverse effects.
Results
Bleomycin resulted in a significantly greater mean percentage reduction in VSS than triamcinolone (72.02% vs. 58.10%; p < 0.00001). A higher proportion of patients treated with bleomycin achieved ≥ 75% improvement (36.8%, n = 25/68) than those treated with triamcinolone (14.7%, n = 10/68; p = 0.0027). Improvements in vascularity, pliability, and scar height were also significantly greater in the bleomycin group, with a mean scar height reduced to 0.8 versus 1.9 mm in the triamcinolone group ( p = 0.003). The reduction in surface area was comparable between the groups ( p = 0.850). Pain ( n = 50, 74%) and hyperpigmentation ( n = 18, 26%) were more frequently observed with bleomycin, whereas skin atrophy ( n = 16, 24%) and telangiectasia ( n = 15, 22%) were more common with triamcinolone.
Conclusion
Both therapies were associated with significant clinical improvement; however, bleomycin demonstrated superior efficacy in reducing scar severity and achieving higher response rates. Larger, multicenter, blinded studies with longer follow‐up periods are warranted to confirm these findings and evaluate long‐term outcomes, including recurrence rates. image
Subjects
MeSH terms (MEDLINE)
Author keywords
Substances
Authors and institutions
- Department of Dermatology, Alluri Sitarama Raju Academy of Medical Sciences, Eluru, Andhra Pradesh, India.
ORCID profiles: Divya Ravali Bandaru, Nirupama Bhagya Lakshmi Tatavarthi
Funding
- Indian Association of Dermatologists, Venereologists and Leprologists (IADVL)
Cite
APA
Bandaru, D. R., Tatavarthi, N. B. L., Rao, D. S., & Amala, R. (2026). Evaluation of Intralesional Bleomycin and Triamcinolone Acetonide in the Treatment of Keloids: A Prospective, Randomized, Open‐Label, Comparative Study. International Journal of Dermatology. https://doi.org/10.1111/ijd.70554
Vancouver
Bandaru DR, Tatavarthi NBL, Rao DS, Amala R. Evaluation of Intralesional Bleomycin and Triamcinolone Acetonide in the Treatment of Keloids: A Prospective, Randomized, Open‐Label, Comparative Study. International Journal of Dermatology. 2026. doi:10.1111/ijd.70554
BibTeX
@article{Bandaru2026,
author = {Bandaru, Divya Ravali and Tatavarthi, Nirupama Bhagya Lakshmi and Rao, Dasika Subba and Amala, Ramala},
title = {Evaluation of Intralesional Bleomycin and Triamcinolone Acetonide in the Treatment of Keloids: A Prospective, Randomized, Open‐Label, Comparative Study},
journal = {International Journal of Dermatology},
year = {2026},
doi = {10.1111/ijd.70554}
}
EUVIMED